{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:17:20Z","timestamp":1775801840701,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.biologicals.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:58:40Z","timestamp":1559365120000},"page":"60-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Octanorm [cutaquig\u00ae], a new immunoglobulin (human) subcutaneous 16.5% solution for injection (165\u202fmg\/mL) \u2013 Biochemical characterization, pathogen safety, and stability"],"prefix":"10.1016","volume":"60","author":[{"given":"Nicola","family":"Gelbmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Z\u00f6chling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Pichotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrej","family":"Mur\u00e1nyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ernegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Pock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"R\u00f6misch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biologicals.2019.05.002_bib1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2217\/imt.14.67","article-title":"An update on the use of immunoglobulin for the treatment of immunodeficiency disorders","volume":"6","author":"Albin","year":"2014","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.biologicals.2019.05.002_bib2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/cei.12485","article-title":"Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease","volume":"179","author":"Jolles","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.biologicals.2019.05.002_bib3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/ACI.0b013e32834c22da","article-title":"Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose","volume":"11","author":"Berger","year":"2011","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.biologicals.2019.05.002_bib4","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s10875-013-9916-z","article-title":"Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina","volume":"33","author":"Bezrodnik","year":"2013","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.biologicals.2019.05.002_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10875-011-9512-z","article-title":"Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease","volume":"31","author":"Wasserman","year":"2011","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.biologicals.2019.05.002_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.transci.2012.03.022","article-title":"Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases","volume":"46","author":"Haddad","year":"2012","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.biologicals.2019.05.002_bib7","unstructured":"EDQM. Eur Pharmacopeia 8.02013."},{"key":"10.1016\/j.biologicals.2019.05.002_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/0001-8686(94)80041-3","article-title":"Particle sizing by quasi-elastic light scattering","volume":"52","author":"Finsy","year":"1994","journal-title":"Adv Colloid Interface Sci"},{"key":"10.1016\/j.biologicals.2019.05.002_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0021-9797(85)90329-7","article-title":"Light scattering in colloidal dispersions: effects of multiple scattering","volume":"105","author":"Dhont","year":"1985","journal-title":"J Colloid Interface Sci"},{"issue":"2","key":"10.1016\/j.biologicals.2019.05.002_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01025246","article-title":"Photon correlation spectroscopy of human IgG","volume":"7","author":"J\u00f8ssang","year":"1988","journal-title":"J Protein Chem"},{"issue":"6","key":"10.1016\/j.biologicals.2019.05.002_bib11","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/jps.20079","article-title":"Challenges in the development of high protein concentration formulations","volume":"93","author":"Shire","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.biologicals.2019.05.002_bib12","series-title":"Grundz\u00fcge biologisch-medizinischer statistik","author":"Biometrie","year":"1974"},{"key":"10.1016\/j.biologicals.2019.05.002_bib13","series-title":"Bacteriological Analytical Manual. Appendix 2: most probable number from serial dilutions","author":"Blodgett","year":"2010"},{"key":"10.1016\/j.biologicals.2019.05.002_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2307\/3001491","article-title":"Estimation of bacterial densities by means of the \"most probable number\"","volume":"6","author":"Cochran","year":"1950","journal-title":"Biometrics"},{"key":"10.1016\/j.biologicals.2019.05.002_bib15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1128\/JCM.32.3.732-739.1994","article-title":"Dilution assay statistics","volume":"32","author":"Myers","year":"1994","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.biologicals.2019.05.002_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.biologicals.2011.06.007","article-title":"Estimating viral titers in solutions with low viral loads","volume":"39","author":"Brownie","year":"2011","journal-title":"Biologicals : J Int Assoc Buddh Stud"},{"key":"10.1016\/j.biologicals.2019.05.002_bib17","series-title":"Bekanntmachung \u00fcber die Zulassung von Arzneimittel: anforderungen an Validierungsstudien zum Nachweis der Virussicherheit von Arzneimitteln aus menschlichem Blut oder Plasma","author":"Bundesgesundheitsamt","year":"1994"},{"key":"10.1016\/j.biologicals.2019.05.002_bib18","series-title":"European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit: note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses","first-page":"14","year":"1996"},{"key":"10.1016\/j.biologicals.2019.05.002_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0166-0934(99)00135-4","article-title":"Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein","volume":"84","author":"Lee","year":"2000","journal-title":"J Virol Methods"},{"key":"10.1016\/j.biologicals.2019.05.002_bib20","series-title":"International conference on harmonization of technical requirements for registration of pharmaceuticals for human use","article-title":"Harmonised Tripartite Guideline: quality of biotechnological products: stability testing of biotechnological\/biological products Q5C","year":"1995"},{"key":"10.1016\/j.biologicals.2019.05.002_bib21","series-title":"International conference on harmonization of technical requirements for registration of pharmaceuticals for human use","article-title":"Harmonised Tripartite Guideline: stability testing of new drug substances and products Q1A (R2)","year":"2003"},{"issue":"4","key":"10.1016\/j.biologicals.2019.05.002_bib22","first-page":"191","article-title":"Distribution of IgG subclass levels in normal adult sera as determined by a competitive enzyme immunoassay using monoclonal antibodies","volume":"3","author":"Aucouturier","year":"1985","journal-title":"Diagn Immunol"},{"key":"10.1016\/j.biologicals.2019.05.002_bib23","series-title":"COMMITTEE FOR MEDICAL PRODUCTS: note for Guidance on virus validation and interpretation of studies validating the inactivation and removal of viruses","author":"CPMP\/BWP\/268\/95","year":"1995"},{"key":"10.1016\/j.biologicals.2019.05.002_bib24","series-title":"European Medicines agency: guideline on plasma-derived medicinal products","author":"EMA\/CHMP\/BWP\/706271\/2010","year":"2010"},{"key":"10.1016\/j.biologicals.2019.05.002_bib25","series-title":"COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE. Guidline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vcjd risk","author":"CPMP\/BWP\/CPMP\/5136\/03","year":"2003"},{"key":"10.1016\/j.biologicals.2019.05.002_bib26","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1537-2995.2004.03420.x","article-title":"Different susceptibility of B19 virus and mice minute virus to low pH treatment","volume":"44","author":"Boschetti","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.biologicals.2019.05.002_bib27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejpb.2010.08.002","article-title":"Rheological and syringeability properties of highly concentrated human polyclonal immunoglobulin solutions","volume":"76","author":"Burckbuchler","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.biologicals.2019.05.002_bib28","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1007\/s11095-014-1611-0","article-title":"Measuring tissue back-Pressure \u2013 in vivo injection forces during subcutaneous injection","volume":"32","author":"Allmendinger","year":"2015","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.biologicals.2019.05.002_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/PPA.S14903","article-title":"Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices","volume":"28","author":"Verdun di Cantogno","year":"2011","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.biologicals.2019.05.002_bib30","series-title":"Production of plasma proteins for pharmaceutic use","first-page":"185","article-title":"Intravenous immunoglobulin G from human plasma \u2013 purification concepts and important quality criteria","author":"Buchacher","year":"2013"},{"issue":"2","key":"10.1016\/j.biologicals.2019.05.002_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2011.01.006","article-title":"Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies","volume":"139","author":"Berger","year":"2011","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.biologicals.2019.05.002_bib32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1157\/13110313","article-title":"Update on the treatment of primary imunodeficiencies","volume":"35","author":"Garc\u00eda","year":"2007","journal-title":"Allergol Immunopathol"},{"key":"10.1016\/j.biologicals.2019.05.002_bib33","first-page":"277","article-title":"Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases","volume":"6","author":"Kobrynski","year":"2012","journal-title":"Biologics"},{"issue":"8760","key":"10.1016\/j.biologicals.2019.05.002_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0140-6736(91)90147-H","article-title":"Home treatment of hypogammaglobulinaemia with subcutaneous gamma globulin by rapid infusion","volume":"338","author":"Gardulf","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2019.05.002_bib35","first-page":"847","volume":"vol. 54","author":"Frenzel","year":"2016"},{"key":"10.1016\/j.biologicals.2019.05.002_bib36","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/trf.13964","article-title":"Inactivation of Zika virus by solvent\/detergent treatment of human plasma and other plasma-derived products and pasteurization of human serum albumin","volume":"57","author":"K\u00fchnel","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.biologicals.2019.05.002_bib37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/trf.13112","article-title":"Anti-A and anti-B hemagglutinin depletion during Chon purification process of 5% immunoglobulin","volume":"55","author":"Salvatore","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.biologicals.2019.05.002_bib38","first-page":"105","volume":"vol. 55","author":"Romberg","year":"2015"},{"key":"10.1016\/j.biologicals.2019.05.002_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fimmu.2019.00040","article-title":"Clinical efficacy, safety and tolerability of a new subcutaneous human immunoglobulin 16.5% (Octanorm [cutaquig\u00ae]) in the treatment of patients with primary immune deficiencies","volume":"10","author":"Kobayashi","year":"2019","journal-title":"Front Immunol"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105619300405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105619300405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T18:07:31Z","timestamp":1608142051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105619300405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":39,"alternative-id":["S1045105619300405"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2019.05.002","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Octanorm [cutaquig\u00ae], a new immunoglobulin (human) subcutaneous 16.5% solution for injection (165\u202fmg\/mL) \u2013 Biochemical characterization, pathogen safety, and stability","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization.","name":"copyright","label":"Copyright"}]}}